{"id":9271,"date":"2012-05-13T18:00:00","date_gmt":"2012-05-13T18:00:00","guid":{"rendered":""},"modified":"2012-05-13T18:00:00","modified_gmt":"2012-05-13T18:00:00","slug":"jav-ekspertai-patvirtino-pirmuosius-vaistus-ziv-prevencijai","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/sveikatos-ir-medicinos-naujienos\/jav-ekspertai-patvirtino-pirmuosius-vaistus-ziv-prevencijai\/9271\/","title":{"rendered":"JAV ekspertai patvirtino pirmuosius vaistus \u017dIV prevencijai"},"content":{"rendered":"<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\"><strong style=\"padding-bottom: 0px; line-height: normal; margin: 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 0px\"><font face=\"\">JAV sveikatos prie\u017ei\u016bros ekspert\u0173 grup\u0117 pirm\u0105 kart\u0105 pritar\u0117 vaistui, kuris b\u016bt\u0173 skiriamas sveikiems pacientams kaip \u017emogaus imunodeficito viruso (\u017dIV\/AIDS) prevencijos priemon\u0117, prane\u0161a BBC.&nbsp;<\/font><\/strong><\/p>\n<p style=\"text-align: justify\">\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\">Specialist\u0173 grup\u0117 rekomendavo JAV maisto ir vaist\u0173 administracijai leisti kapsules &quot;Truvada&quot; kaip prevencin\u012f vaist\u0105 skirti \u017dIV rizikos grupei priklausantiems asmenims. JAV maisto ir vaist\u0173 kontrolieriai neprivalo klausyti specialist\u0173 grup\u0117s patarim\u0173, bet paprastai elgiasi pagal rekomendacijas.<\/p>\n<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\">JAV maisto ir vaist\u0173 administracija jau yra patvirtinusi &quot;Truvada&quot; kapsules AIDS sergantiems pacientams, kurie jas turi vartoti kasdien kartu su kitais vaistais. Kai kurie sveikatos prie\u017ei\u016bros darbuotojai ir aktyvistai prie\u0161tarauja vaisto skyrimui prevenciniais tikslais. Bet korespondentai teigia, kad tai gali b\u016bti didelis \u017eingsnis \u012f priek\u012f kovoje su AIDS.<\/p>\n<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\">Kritikai teigia, kad leidus sveikiems asmenims skirti prevencin\u012f vaist\u0105, jis suteiks perd\u0117t\u0105 saugumo jausm\u0105. Be to baiminamasi, kad gali i\u0161sivystyti vaistams atspari \u017dIV viruso atmaina. Sveikatos prie\u017ei\u016bros darbuotojai teigia, kad &quot;Truvada&quot; piliules reikia vartoti nuolat ir kiekvien\u0105 dien\u0105, o da\u017eniausiai pacientai n\u0117ra tokie drausmingi. Nerim\u0105 kelia ir didel\u0117 &quot;Truvada&quot; kaina, d\u0117l kurios gali suma\u017e\u0117ti l\u0117\u0161\u0173, skiriam\u0173 pigesn\u0117ms alternatyvoms.<\/p>\n<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\">Lietuvos sveikata<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p style=\"text-align: justify; padding-bottom: 0px; line-height: normal; margin: 5px 0px; padding-left: 0px; padding-right: 0px; font-family: Arial, Verdana, Helvetica, sans-serif; padding-top: 10px\">Specialist\u0173 grup\u0117 rekomendavo JAV maisto ir vaist\u0173 administracijai leisti kapsules &quot;Truvada&quot; kaip prevencin\u012f vaist\u0105 skirti \u017dIV rizikos grupei priklausantiems asmenims. JAV maisto ir vaist\u0173 kontrolieriai neprivalo klausyti specialist\u0173 grup\u0117s patarim\u0173, bet paprastai elgiasi pagal rekomendacijas.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[354,132],"site":[],"post_item_type":[27344],"class_list":["post-9271","post","type-post","status-publish","format-standard","hentry","category-gydymo-naujienos","tag-darbuotojai","tag-ziv"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/9271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=9271"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/9271\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=9271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=9271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=9271"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=9271"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=9271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}